BURBANK, CA--(Marketwire - July 27, 2011) -
Imaging3™, Inc. (OTCBB: IMGG
), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, today announced that they will soon be completing the first phase of the FDA resubmission strategy.
Dean Janes, Chairman and CEO of Imaging 3, commented, "I am pleased to announce that Imaging3 will soon be completing its first phase of our FDA resubmission strategy. We are currently finalizing our imaging protocol document to submit to the FDA with the purpose of requesting a face to face meeting. The delay in completing this document and preparations for this meeting has been mostly due to combining all the efforts and revisions from each consultant involved with this process. I expect to have the final revision soon and forward that document along with our meeting request. I will of course inform you in the form of a newsletter and/or press release once this has occurred."
Dean also commented, "As mentioned in a previous newsletter, I/We would be providing further video demonstrations and broadcast them on the program Money TV. This is still going to occur but our efforts have been focused on finishing this phase of our FDA resubmission strategy. Once we have completed this phase we will again be focused on providing another video demonstration or several."
The company also announced that they would be hosting an open house for shareholders and the general public on Friday August 19th, 2011 from 12pm to 3pm PDT. During the open house, guests will be able to meet officers of the company, receive an update on the progress of the DViS and our FDA resubmission strategy as well as a Q&A session with the CEO. A technical demonstration of the DViS will also be performed for those in attendance. All participants are required to RSVP via email with their contact information including; name, address, phone, and email information no later than Friday August 12th, 2011. No person will be allowed to attend without sending an RSVP by the above mentioned date and all people in attendance will be required to show photo identification to attend. Those wishing to see the technical demonstration will be required to sign a Non Disclosure Agreement.
Please RSVP for the Open House to the email@example.com email address.
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at http://www.imaging3.com for more information
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, technological obsolescence, competition from other medical instrument(s) and imaging companies, lack of capital, unexpected costs, failure or delay of FDA approval, absence of revenue, the impact on the national and local economies resulting from an economic recession or terrorist actions, and U.S. actions subsequently; unavailability of financing for the Company or its customers, product malfunction and potential product liability claims, and other factors detailed in reports filed by the Company.